Immunization, Secondary

2 trials

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB), in Havana, Finlay Institute of Vaccines (IFV)

Conditions

COVID-19COVID-19 COVID-19 SARS-CoV-2

Phase 2

Active, not recruitingRPCEC00000398

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaCOVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-22Updated: 2026-08-10

Unknown Phase

To evaluate the immunogenicity and safety of SOBERANA® 02 and SOBERANA® Plus as booster of immunity against the omicrom variant of SARS-CoV-2, in adult subjects

Active, not recruitingRPCEC00000424

Finlay Institute of Vaccines (IFV)COVID-19

Start: 2023-05-22Target: 306Updated: 2026-08-10

Related Papers

Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial

Vaccines2024-09-012 citations